No Data
No Data
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Tandem Diabetes Announces NEJM Publication Of Control-IQ+ Trial For Type 2 Diabetes, Showing Significant A1C Reductions Of 0.9% Overall And 2.3% For A1C ≥9%, Meeting Primary Endpoint
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $27
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes With Control-IQ+ AID Technology in Type 2 Diabetes
Express News | Tandem Diabetes Care Inc : TD Cowen Cuts Target Price to $27 From $40
Express News | Tandem Diabetes Care Launches New Control-Iq+ Automated Insulin Delivery Technology in the United States